This Stock Is Up More than 560% This Year, but It Could Drop by 38%, According to Wall Street
Have Moderna’s shares risen too much, too fast?
Moderna's (NASDAQ:MRNA) stock has surged over 560% this year, outpacing the S&P 500's modest 14% gain. The biotech's strong clinical and regulatory progress, including the approval of its influenza vaccine mFLUSIVA for patients aged 50 and older, has contributed to this impressive performance. However, Wall Street analysts are expressing concerns about the stock's valuation, with an average price target of $121 suggesting a potential 38% drop from its current level.
Brief written by urgent.news from Motley Fool's own syndicated text. Machine-written — may contain errors; check the original before relying on it.